American Journal of Ophthalmology
Volume 143, Issue 2 , Pages 335-338 , February 2007

Anti-VEGF Bevacizumab (Avastin®) for Radiation Optic Neuropathy

  • Paul T. Finger, MD

      Affiliations

    • Corresponding Author InformationInquiries to Paul T. Finger, MD, The New York Eye Cancer Center, 115 East 61st Street, New York City, New York, 10021

,Accepted 1 September 2006.

References 

  1. Miller NR. Radiation-induced optic neuropathy: still no treatment. Clin Experiment Ophthalmol. 2004;32:233–235
  2. Finger PT, Murphree AL. Ophthalmic brachytherapy: treatment of choroidal melanoma and retinoblastoma. In:  Peyman GA,  Meffert S,  Conway MD,  Chou F editor. Vitreoretinal surgical techniques. London, United Kingdom: Martin Dunitz; 2001;p. 403–418
  3. Levy RL, Miller NR. Hyperbaric oxygen therapy for radiation-induced optic neuropathy. Ann Acad Med Singapore. 2006;35:151–157
  4. Gardiner TA, Amoaku WM, Archer DB. The combined effect of diabetes and ionizing radiation on the retinal vasculature of the rat. Curr Eye Res. 1993;12:1009–1014
  5. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005;112:1048–1053

 This study was supported in part by a Grant from John and Myrna Daniels, Toronto, Ontario, Canada, and The EyeCare Foundation, New York, New York. The author indicates no financial conflict of interest. The author was involved in collection, management, analysis and interpretation of data, and preparation of the data and revision including references; involved in collection of data; and involved in management, statistical analysis and interpretation of the data, and preparation of the manuscript.

PII: S0002-9394(06)01067-1

doi: 10.1016/j.ajo.2006.09.014

American Journal of Ophthalmology
Volume 143, Issue 2 , Pages 335-338 , February 2007

Article Tools

* Image Usage & Resolution